Prudential PLC Boosts Stock Holdings in CVS Health Corporation $CVS

Prudential PLC lifted its stake in shares of CVS Health Corporation (NYSE:CVS) by 428.4% during the fourth quarter, Holdings Channel reports. The fund owned 148,805 shares of the pharmacy operator’s stock after acquiring an additional 120,642 shares during the period. Prudential PLC’s holdings in CVS Health were worth $11,809,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Vise Technologies Inc. increased its position in shares of CVS Health by 45.6% during the fourth quarter. Vise Technologies Inc. now owns 34,151 shares of the pharmacy operator’s stock worth $2,710,000 after acquiring an additional 10,689 shares during the period. Continuum Advisory LLC increased its position in shares of CVS Health by 3.7% during the fourth quarter. Continuum Advisory LLC now owns 78,973 shares of the pharmacy operator’s stock worth $6,267,000 after acquiring an additional 2,825 shares during the period. Daiwa Securities Group Inc. raised its holdings in shares of CVS Health by 3.4% in the 4th quarter. Daiwa Securities Group Inc. now owns 204,969 shares of the pharmacy operator’s stock valued at $16,266,000 after purchasing an additional 6,733 shares in the last quarter. Platform Wealth Management LLC acquired a new stake in shares of CVS Health in the 4th quarter valued at $6,853,000. Finally, State of Wyoming raised its holdings in shares of CVS Health by 62.4% in the 4th quarter. State of Wyoming now owns 12,717 shares of the pharmacy operator’s stock valued at $1,009,000 after purchasing an additional 4,888 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Health was upgraded to a Zacks Rank #2 (Buy), reflecting improved earnings optimism and adding to the bullish tone around the stock. Article Title
• Positive Sentiment: Broker sentiment remains constructive on CVS Health, with recent coverage pointing to favorable views from Wall Street analysts and broader confidence in the company’s outlook. Article Title
• Positive Sentiment: The managed-care group rallied after analysts cited softer medical cost and utilization trends across the sector, which can support margins and spill over positively to CVS Health. Article Title
• Neutral Sentiment: CVS Health highlighted community and affordable-housing projects in New Jersey and Massachusetts, underscoring its corporate social responsibility efforts, but these announcements are unlikely to move the stock materially. Article Title
• Neutral Sentiment: Media coverage noted CVS Health is up about 8.5% since its last earnings report and asked whether the rally can continue, mainly reflecting investor attention on post-earnings momentum rather than a new catalyst. Article Title
• Neutral Sentiment: CVS CEO comments on AI, “super apps,” and primary care suggest longer-term strategy focus, but there was no immediate financial update in the coverage. Article Title
• Neutral Sentiment: Additional community partnership news, including a job training lab in Lincoln Heights, is supportive of the brand but not a direct earnings driver. Article Title

Insider Transactions at CVS Health

In other news, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the sale, the executive vice president directly owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Larry Robbins sold 370,462 shares of the company’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the sale, the director directly owned 4,824,799 shares of the company’s stock, valued at $450,877,466.55. The trade was a 7.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,441,551 shares of company stock valued at $323,703,977 over the last ninety days. Corporate insiders own 0.85% of the company’s stock.

CVS Health Price Performance

Shares of CVS opened at $96.11 on Friday. CVS Health Corporation has a 1-year low of $58.50 and a 1-year high of $98.43. The stock has a market cap of $122.62 billion, a PE ratio of 42.34, a price-to-earnings-growth ratio of 0.93 and a beta of 0.62. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The firm has a fifty day moving average price of $84.13 and a 200 day moving average price of $80.03.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. During the same period in the previous year, the company earned $2.25 earnings per share. CVS Health’s quarterly revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, sell-side analysts anticipate that CVS Health Corporation will post 7.44 EPS for the current year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd were issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend was Thursday, April 23rd. CVS Health’s dividend payout ratio is presently 117.18%.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on CVS. Morgan Stanley raised their price objective on shares of CVS Health from $106.00 to $111.00 and gave the company an “overweight” rating in a report on Thursday. Truist Financial raised their price objective on shares of CVS Health from $102.00 to $108.00 and gave the company a “buy” rating in a report on Monday, June 1st. DA Davidson raised their price objective on shares of CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Barclays raised their price objective on shares of CVS Health from $101.00 to $106.00 and gave the company an “overweight” rating in a report on Tuesday, May 26th. Finally, Wolfe Research reduced their price objective on shares of CVS Health from $100.00 to $97.00 and set an “outperform” rating on the stock in a report on Monday, March 2nd. Twenty-two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $99.88.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.